| Literature DB >> 36015262 |
Sabna Kotta1,2, Hibah Mubarak Aldawsari1,2, Shaimaa M Badr-Eldin1,2, Anroop B Nair3, Kamal Yt4.
Abstract
Polymeric micelles (PMs) have made significant progress in drug delivery applications. A robust core-shell structure, kinetic stability and the inherent ability to solubilize hydrophobic drugs are the highlights of PMs. This review presents the recent advances and understandings of PMs with a focus on the latest drug delivery applications. The types, methods of preparation and characterization of PMs are described along with their applications in oral, parenteral, transdermal, intranasal and other drug delivery systems. The applications of PMs for tumor-targeted delivery have been provided special attention. The safety, quality and stability of PMs in relation to drug delivery are also provided. In addition, advanced polymeric systems and special PMs are also reviewed. The in vitro and in vivo stability assessment of PMs and recent understandings in this area are provided. The patented PMs and clinical trials on PMs for drug delivery applications are considered indicators of their tremendous future applications. Overall, PMs can help overcome many unresolved issues in drug delivery.Entities:
Keywords: critical micelle concentration; drug delivery; oral; polymeric micelles; tumor-targeted
Year: 2022 PMID: 36015262 PMCID: PMC9412594 DOI: 10.3390/pharmaceutics14081636
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Different types of polymers used for micelle fabrication and their methods of preparation.
| Sl. No. | Polymer | Method of Preparation | Drug | Reference |
|---|---|---|---|---|
| 1 | Block copolymer of mPEG (5 kDa)-PCL (2 kDa) | Continuous processing | Curcumin | [ |
| 2 | Poly(ethylene glycol)- | Self-assembly | Dactolisib | [ |
| 3 | Chitosan-stearic acid | Self-assembly | Doxorubicin | [ |
| 4 | mPEG-PLGA | Solvent evaporation method | Rotigotine | [ |
| 5 | disteraroylphosphatidylethanolamine-(PEG) | Solvent evaporation method | Paclitaxel | [ |
| 6 | Hyaluronan | Solvent evaporation method | Coenzyme Q10 | [ |
| 7 | Hexyl-hyaluronan and oleyl-hyaluronan | Solvent evaporation method | Curcumin | [ |
| 8 | Coumarin and imidazole grafted poly(ethylene glycol)-b-poly(l-lysine) | Mixing and dialysis | Doxorubicin | [ |
| 9 | mPEG poly(ethylene glycol)- | Thin-film hydration method | Hypocrellin A (photosensitizer) | [ |
| 10 | Pluronic® F127 | Thin-film hydration technique | ZileutonTM | [ |
| 11 | Carboxymethyl chitosan-rhein conjugate | Self-assembly | Paclitaxel | [ |
| 12 | Gallic acid-Chitosan-D-α-tocopherol PEG 1000 succinate | Ultrasonic emulsification | Paclitaxel | [ |
| 13 | D-α-tocopherol PEG 1000 succinate (TPGS) | Thin-film dispersion | Laquinimod | [ |
| 14 | Poloxamer | Not mentioned | Doxorubicin | [ |
| 15 | Functionalized poloxamer | Not mentioned | Doxorubicin | [ |
| 16 | Methoxypoly(ethylene glycol)- | Self-assembly | Doxorubicin | [ |
| 17 | triphenylphosphonium (TPP) grafted poly(ethylene glycol)(PEG)-poly( | Solvent evaporation method | Doxorubicin | [ |
| 18 | Poloxamer | Self-assembly | Mycophenolic acid | [ |
| 19 | Methoxy poly(ethylene glycol)- | Solvent evaporation method | Doxorubicin | [ |
| 20 | PDEA-b-P(ABMA-co-OEGMA) | Sonication | 6-mercaptopurine and doxorubicin | [ |
| 21 | mPEG-b-P(Deta-NBCF)LG | Self-assembly | Cytochrome C | [ |
| 22 | Chitosan-lecithin | Sonication | Thymoquinone | [ |
| 23 | Poly(aspartic acid) derivatives with phenylborate serine side groups | Dialysis | Doxorubicin | [ |
| 24 | Cholic acid conjugated poly (bis (carboxyphenoxy) phosphazene) | Ultrasonication | Paclitaxel | [ |
| 25 | Poly-(lactic-co-glycolic)-b-poly (ethylene glycol)-maleimide | Dialysis method | Nilotinib | [ |
| 26 | Poly (α-azide caprolactone-co-caprolactone)-b-poly (2-methacryloyloxyethyl phosphorylcholine) | Dialysis method | Doxorubicin and 7-Ethyl-10-hydroxycamptothecin | [ |
| 27 | Poly (ethylene glycol)-block-poly (ε-caprolactone) | Thin-film hydration | SP600125 and Bone Morphogenetic Protein-2 | [ |
Figure 1(A) Schematic representation of continuous processing method for micelle formation. Reprinted with permission from [14] © Elsevier 2020. (B) Schematic representation of the design of multi-responsive block copolymers having spirogyra end groups by atom transfer polymerization method. Reprinted with permission from [47] © Elsevier 2019.
Figure 2Various characterization techniques for PMs: (A) Cryo-TEM images surfactant copolymer complex micelle. Reprinted with permission from [71]. (B) AFM image of self-assembled cholesterol end-capped polymeric micelle. Reprinted with permission from [49]. (C) SEM image of self-assembled cholesterol end-capped polymeric micelle. Reprinted with permission from [49]. (D) SAXS profile of bromobenzene (BrBz) and 4-bromophenol (BrPh) encapsulated PMs made up of poly(ethylene glycol)-b-poly(tert-butyl methacrylate) (PEG-b-PtBMA). Reprinted with permission from [72].
Figure 3(A) Effect of exposure of NIR light on core cross-linked and non-core cross-linked polymeric micelles. (B) Application of electrostatically attractive PMs on the rheology of HA gel and solutions.
Figure 4(A) Histological micrographs (10× and 40× magnification) of paw tissues of normal, complete Freund’s adjuvant (CFA) control, Celecoxib (CXB), Celebrex®, previously developed solid dispersion (SD6) and optimal CXB micelles (M3) in CFA-induced rats with H&E staining. Reproduced with permission from [81] © 2020 Elsevier. (B) Hematoxylin-Eosin (HE), Alcian Blue Periodic acid Schiff (AB-PAS) and Masson staining results of the colons of colitis mice after treatment with different formulations (20× magnification). Reproduced with permission from [26] © 2020 Elsevier.
Figure 5Design and mechanism of the action of nilotinib-loaded functionalized micelles for liver fibrosis.
Figure 6(A) Preparation of (mPEG-b-PCL) HA micelle for photodynamic antibacterial activity. (B) Antibacterial activity of micelles at different irradiation times. (C) Total bacterial count in blood, spleen and liver after dark and light irradiation with micelles for 24 and 48 h. Reprinted with permission from [22] © Elsevier 2019. ** p < 0.01, *** p < 0.001. (D) Schematic representation of fabrication, characterization and evaluation of CS-g-PCL/MA–PZA micelles. Reprinted with permission from [84] © Elsevier 2020.
Figure 7Synthesis of HA micelle and its internalization and accumulation pattern on skin layers.
Figure 8Fabrication of dual targeting and dual-responsive polymeric micelle for mitochondrial targeting.
Figure 9(A) Coumarin and imidazole grafting for enhanced drug loading and pH-dependent drug release in doxorubicin-loaded PMs. (B) CR-conjugate polymer synthesis and activity on the colorectal tumor.
Figure 10(A) Schematic representation of micelle formation, gelation with Fe3+ and pH-, UV- and GSH-triggered drug release mechanism. (B) Intracellular release of multi-responsive nanogels encapsulated with anticancer drugs.
Figure 11Diagrammatic representation of special types of PMs.
Recent patents related to PMs and their drug delivery applications.
| Sl. No. | Publication No. (Year) | Title | Summary of Invention |
|---|---|---|---|
| 1. | WO/2020/228265 (2020) | “Pharmaceutical compositions containing mixed PMs” | Describes drug-loaded 1–1000 nm-sized mixed PMs. |
| 2. | 111686261 (2020) | “Adriamycin-polymeric micelles-nucleophosmin-binding protein (ADR-PMs-NMBP) with anti-acute lymphoblastic leukemia (ALL) activity and preparation method of ADR-PMs-NMBP” | Describes the preparation method of the ADR-PMs-NMBP. |
| 3. | 111686076 (2020) | “Doxorubicin-loaded polymeric micelle as well as preparation method and application thereof” | Describes the preparation and applications of DOX-loaded PMs. Two amphipathic PMs were described for the purpose. |
| 4. | 201811043353 (2020) | “Improved wound healing topical composition of thymoquinone” | Thymoquinone-loaded PMs are prepared using chitosan and soy lecithin for wound healing. |
| 5. | CN111658783A (2020) | “Switch type glucose-responsive double-layer cross-linked polymer micelle drug delivery system and preparation method and application thereof” | Glucose-responsive double-layered cross-linked PM. |
| 6. | CN111978520A (2020) | “PEG monomethyl ether-polylactic acid segmented copolymer, polymer micelle medicine and preparation method” | Preparation of PMs using PEG monomethyl ether-polylactic acid segmented copolymer for medical application. |
| 7. | CN111978553A (2020) | “Triple-stimulus responsive interfacial crosslinked polymer micelle and preparation method and application thereof” | Triple stimulus-responsive hydrophobic polymer-based PMs. Enhanced drug loading and rapid drug release to stimulus. |
| 8. | CN111330014A (2020) | “Acid-responsive cross-linked polymer prodrug and preparation method and application thereof” | Includes a vinyl alkyl ether acrylate monomer. Provides high drug loading for hydroxyl-group-containing drugs. |
| 9. | CN111888357A (2020) | “Chemotherapy drug-co-loaded crizotinib prodrug polymer micelle and preparation method thereof” | PM is prepared by self-assembling an amphiphilic diblock copolymer and hydrophobic crizotinib. |
| 10. | CN111214438A (2020) | “Method for preparing doxorubicin-loaded polymer micelles with different sizes” | Size controlled doxorubicin-loaded PMs using a micro-reaction system. |
| 11. | United States Patent 10,799,455 (2020) | “Micelles containing alpha-lipoic acid as a transdermal drug delivery system” | PMs with alpha-lipoic acid and vinpocetine for transdermal delivery. |
| 12. | 109966508 (2019) | “pH-sensitive targeting polymeric micelles PPi-Far-PMs, and preparation method and application thereof” | PMs for the release of farnesol to the decayed tooth by targeting the pyrophosphate and acid environment. |
| 13. | WO/2019/129657 (2019) | “Actively targeted polymeric micelles for drug and gene delivery” | PMs prepared of an amphiphilic block copolymer of polyoxyethylene and polyoxypropylene blocks. |
| 14. | CN108524933 (2018) | “Carrier capable of inhibiting tumor multidrug resistance and preparation method thereof” | PMs are prepared by targeting molecule-PEG-pyrene amphiphilic polymer system. |
Present clinical trials listed in the clinical trial registry (ClinicalTrials.gov) on PM-based drug delivery systems.
| Sl. | ClinicalTrials.gov Identifier | Details | Phase (Status) |
|---|---|---|---|
| 1. | NCT00912639 | Cremophor EL-free PMs of paclitaxel (Genexol-PM®) for taxane-pretreated recurrent breast cancer | Phase 4 (Not available) |
| 2. | NCT01023347 | A comparative trial between two strategies; Paclitaxel (Genexol®) and cisplatin vs. Genexol-PM® and cisplatin, in non-small cell lung cancer | Phase 2 (Completed) |
| 3. | NCT00886717 | Paclitaxel-loaded PMs in advanced ovarian cancer | Phase 2 |
| 4. | NCT03585673 | Docetaxel-loaded PMs in esophagus squamous cell carcinoma | Phase 2 |
| 5. | NCT01426126 | Genexol-PM® in advanced urothelial cancer earlier treated with gemcitabine and platinum | Phase 2 (Completed) |
| 6. | NCT02639858 | Docetaxel-loaded PMs in recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 |
| 7. | NCT00111904 | Paclitaxel-loaded PMs in unresectable locally advanced or metastatic pancreatic cancer | Phase 2 (Completed) |
| 8. | NCT01770795 | Genexol-PM® in untreated metastatic non-small cell lung cancer patients | Phase 2 (Completed) |
| 9. | NCT02739529 | Genexol-PM® in gynecologic cancer | Phase 1 |
| 10. | NCT00882973 | Genexol-PM® in advanced pancreatic cancer | Phase 1 |